Inclusion Criteria:

          -  With confirmed diagnosis of primary or secondary AML according to WHO classification
             2016, with measurable disease. Eligible participants need to have received
             standard-of-care (SOC) and have no other SOC options available Participants who are
             not willing to receive SOC will be not eligible. Two groups of participants (Group I -
             hematologic relapsed/refractory and Group II - molecular relapsed/refractory) will be
             included

          -  Participants who have received hematopoietic stem cell transplant (HSCT) must have the
             HSCT performed ≥ 90 days prior to the first dose of RO7283420 on Cycle 1 Day 1, having
             demonstrated hematological engraftment and do not have an active Graft versus Host
             Disease, not requiring immunosuppressive treatment (including but not limited to
             cyclosporine, tacrolimus, sirolimus, and mycophenolate), which must be stopped at
             least 28 days prior to the first dose of RO7283420 on Cycle 1 Day 1

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Peripheral blast counts =< 20,000/mm3 on Cycle 1 Day 1 prior to the first dosing

          -  Confirmed genotype of HLA-A*02

          -  Adequate renal (a creatinine clearance of >=50 mL/min as calculated according to the
             Cockroft-Gault formula) and adequate liver test results

          -  Male or female participants agree to use contraception and the abstinence requirements
             to prevent exposure of an embryo to the study treatment

        Exclusion Criteria:

          -  Acute promyelocytic leukemia (APL)

          -  Core Binding Factor (CBF)-AML Note: participants with r/r CBF-AML after at least 2
             salvage attempts can be enrolled into the study

          -  Group II only: participants with normal karyotype and a favorable molecular profile
             according to ELN guideline 2017

          -  Participants with active bacterial, fungal or viral infection considered by the
             Investigator to be clinically uncontrolled or of unacceptable risk upon the induction
             of neutropenia (i.e. participants who are or should be on antimicrobial agents for the
             treatment of active infection)

          -  Grade >= 2 glomerular proteinuria at screening or on Cycle 1 Day 1 prior to the first
             dosing.

          -  Another primary malignancy (other than AML) that requires active therapy. Adjuvant
             hormonal therapy is allowed

          -  Clinical evidence or history of central nervous system (CNS) leukemia

          -  Presence of extramedullary disease at screening

          -  Current or past history of CNS disease, such as stroke, CNS inflammation, epilepsy,
             CNS vasculitis, or neurodegenerative disease

          -  Participants who have a history of clinically significant liver disease, including
             liver cirrhosis (e.g. Child-Pugh class B and C) or participants who have a history of
             active or chronic infectious hepatitis unless serology demonstrates clearance of
             infection

          -  Participants who might refuse to receive blood products and/or have known
             hypersensitivity to any of the components of RO7283420, tocilizumab, or dasatinib